Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study

References

• Gorevic PD, Prelli FC, Wright J, et al. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest. 1989;83(3):836–843. doi: 10.1172/JCI113966.
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-Sequence transthyretin (isoleucine 122) in Late-Onset cardiac amyloidosis in black americans. N Engl J Med. 1997;336(7):466–473. doi: 10.1056/NEJM199702133360703.
   PubMed Web of Science ®Google Scholar
• Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–443. doi: 10.1038/s41586-020-2308-7.
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Alexander AA, Tagoe C, et al. The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in africa. Mol Genet Genomic Med. sept 2016;4(5):548–556. doi: 10.1002/mgg3.231.
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Alexander AA, Tagoe C, et al. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 african–americans. Amyloid. 2015;22(3):171–174. doi: 10.3109/13506129.2015.1051219.
   PubMed Web of Science ®Google Scholar
• Coniglio AC, Segar MW, Loungani RS, et al. Transthyretin V142I genetic variant and cardiac remodeling, injury, and heart failure risk in black adults. JACC Heart Fail. 2022;10(2):129–138. doi: 10.1016/j.jchf.2021.09.006.
   PubMed Web of Science ®Google Scholar
• Damrauer SM, Chaudhary K, Cho JH, et al. Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of african or hispanic/latino ancestry. JAMA. 10 déc 2019;322(22):2191–2202. doi: 10.1001/jama.2019.17935.
   PubMed Web of Science ®Google Scholar
• Murray MF, Miller EJ. Can We manage presymptomatic TTR V142I related risk? JACC Heart Fail. 2022;10(2):139–141. doi: 10.1016/j.jchf.2021.10.009.
   PubMed Web of Science ®Google Scholar
• Buxbaum J, Jacobson DR, Tagoe C, et al. Transthyretin V122I in african americans with congestive heart failure. J Am Coll Cardiol. 2006;47(8):1724–1725. doi: 10.1016/j.jacc.2006.01.042.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–2806. doi: 10.1093/eurheartj/ehx589.
   PubMed Web of Science ®Google Scholar
• Transmissions des maladies génétiques - Orphanet [Internet]. Ile de France: INSERM; 2007. https://www.orpha.net/orphaschool/formations/transmission/ExternData/InfoTransmission-Dreamweaver/Transmission.pdf
   Google Scholar
• Wexler NS, Young AB, Tanzi RE, et al. Homozygotes for huntington’s disease. Nature. 12 Mars. 1987;326(6109):194–197. doi: 10.1038/326194a0.
   PubMed Web of Science ®Google Scholar
• Raimondo A, Chakera AJ, Thomsen SK, et al. Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability. Hum Mol Genet. 2014;23(24):6432–6440. doi: 10.1093/hmg/ddu360.
   PubMed Web of Science ®Google Scholar
• Ortiz MF, Rodríguez-García MI, Hermida-Prieto M, et al. A homozygous MYBPC3 gene mutation associated with a severe phenotype and a high risk of sudden death in a family with hypertrophic cardiomyopathy. Rev Esp Cardiol. 2009;62(5):572–575. doi: 10.1016/s1885-5857(09)71841-9.
   PubMed Web of Science ®Google Scholar
• Tojo K, Sekijima Y, Machida K, et al. Amyloidogenic transthyretin Val30Met homozygote showing unusually early-onset familial amyloid polyneuropathy. Muscle Nerve. 2008;37(6):796–803. doi: 10.1002/mus.21028.
   PubMed Web of Science ®Google Scholar
• Reddi HV, Jenkins S, Theis J, et al. Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the african American population in the seventh decade of life. J Mol Diagn. 2014;16(1):68–74. doi: 10.1016/j.jmoldx.2013.08.001.
   PubMed Web of Science ®Google Scholar
• Poggio ED, Wang X, Greene T, et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol. 2005;16(2):459–466. doi: 10.1681/ASN.2004060447.
   PubMed Web of Science ®Google Scholar
• Kharoubi M, Bézard M, Broussier A, et al. Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis. Front Cardiovasc Med. 14 March 2023;10:1124660. doi: 10.3389/fcvm.2023.1124660.
   PubMed Web of Science ®Google Scholar
• Grogan M, Scott CG, Kyle RA, et al. Natural history of Wild-Type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. sept 2016;68(10):1014–1020. doi: 10.1016/j.jacc.2016.06.033.
   PubMed Web of Science ®Google Scholar
• Cheng RK, Levy WC, Vasbinder A, et al. Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC CardioOncol. 2020;2(3):414–424. Sepdoi: 10.1016/j.jaccao.2020.06.007.
   PubMedGoogle Scholar
• Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215–219. doi: 10.1080/13506129.2018.1549825.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Riva L, Quarta CC, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid. 2008;15(1):40–48. doi: 10.1080/13506120701815373.
   PubMed Web of Science ®Google Scholar
• Gentile L, Di Bella G, Minutoli F, et al. Description of a large cohort of caucasian patients with V122I ATTRv amyloidosis: neurological and cardiological features. J Peripher Nerv Syst. sept 2020;25(3):273–278. doi: 10.1111/jns.12385.
   PubMed Web of Science ®Google Scholar
• Ammirati E, Marziliano N, Vittori C, et al. The first caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation. Amyloid. 2012;19(2):113–117. doi: 10.3109/13506129.2012.666509.
   PubMed Web of Science ®Google Scholar
• Cappelli F, Frusconi S, Bergesio F, et al. The Val142Ile transthyretin cardiac amyloidosis: not only an Afro-American pathogenic variant? A single-Centre italian experience. J Cardiovasc Med (Hagerstown). 2016;17(2):122–125. doi: 10.2459/JCM.0000000000000290.
   PubMed Web of Science ®Google Scholar
• Batra J, Rosenblum H, Cappelli F, et al. Racial differences in Val122Ile-Associated transthyretin cardiac amyloidosis. J Card Fail. 2022;28(6):950–959. doi: 10.1016/j.cardfail.2021.12.016.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi: 10.1056/NEJMoa1805689.
   PubMed Web of Science ®Google Scholar
• Oghina S, Josse C, Bézard M, et al. Prognostic value of N-Terminal Pro-Brain natriuretic peptide and High-Sensitivity troponin T levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment. JCM. 2021;10(21):4868. 22 oct doi: 10.3390/jcm10214868.
   Google Scholar
• Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2016;68(2):161–172. doi: 10.1016/j.jacc.2016.03.596.
   PubMed Web of Science ®Google Scholar
• Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2 Juill. 2019;140(1):16–26. doi: 10.1161/CIRCULATIONAHA.118.038169.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493–502. doi: 10.1056/NEJMoa2107454.
   PubMed Web of Science ®Google Scholar